---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000335"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:44:24.651678+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027

## Summary
- FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).
- Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).
- Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.
- Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.
- New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started.

## SEC filing metadata
- accession: 0001193805-24-000335
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/e619328_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000335
- JSON: https://secwatch.observer/filing/0001193805-24-000335.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000335.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the three months ended December 31, 2023 results: revenue $34.0 million.
  - Period: the three months ended December 31, 2023
  - Revenue: $34.0 million
  - Result: reported results
  source text: For the three months ended December 31, 2023, revenue recognized was $34.0 million compared with $160.3 million for the three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the year ended December 31, 2023 results: revenue $169.9 million.
  - Period: the year ended December 31, 2023
  - Revenue: $169.9 million
  - Result: reported results
  source text: For the year ended December 31, 2023, we reported revenue of $169.9 million compared with $206.0 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.